Citations

Clear

1434 citation(s) found for "Uk, Nathan".

A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Alexander, Barbara D. , Arendrup, Maiken Cavling , Babady, Esther , Balada-Llasat, Joan-Miquel, Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Fuller, Jeff, Gibas, Connie Fe C., Glasgow, Heather, Gräser, Yvonne , Groll, Andreas H. , Haase, Gerhard , Hanson, Kimberly E. , Harrington, Amanda, Hayden, Randall T. , Hubka, Vít , Johnson, Kristie, Li, Ruoyu , Lanternier, Fanny , Leal, Sixto M. , Lee, Francesca , Luethy, Paul M. , Kwon‐Chung, Kyung J., Palavecino, Elizabeth , Pancholi, Preeti , Pappas, Peter G. , Procop, Gary W. , Rhoads, Daniel D. , Riedel, Stefan , Stevens, Bryan S. , Sullivan, Kaede Ota, Vergidis, Paschalis , Roilides, Emmanuel , Seyedmousavi, Amir, Tao, Lili , Vicente, Vânia Aparecida , Vitale, Roxana G. , Wengenack, Nancy L. , Westblade, Lars F. , Wiederhold, Nathan P. , White, Lewis, Wojewoda, Christina , Babady, N. Esther , Seyedmousavi, Seyedmojtaba , de Hoog, Sybren , Walsh, Thomas J , Ahmed, Sarah A , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Groll, Andreas H , Hanson, Kimberly , Hayden, Randall T , Hoenigl, Martin , Kus, Julianne V , Meis, Jacques F , Leal, Sixto M , Lockhart, Shawn R. , Luethy, Paul , Kwon-Chung, Kyung J , Nguyen, M Hong , Pancholi, Preeti , Procop, Gary W , Rhoads, Daniel D , Riedel, Stefan , Vergidis, Paschalis , Vitale, Roxana G , Wengenack, Nancy L , White, Lewis , Wojewoda, Christina M , Zhang, Sean X , Cornely, Oliver A , Roilides, Emmanuel , Wiederhold, Nathan , Bai, Feng‐Yan , Chowdhary, Anuradha , Clark, Andrew, Dingle, Tanis C. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Guillot, Jacques , Hawksworth, David L. , Hoenigl, Martin , Kus, Julianne V. , Lackner, Michaela , Martin, Isabella W. , Meyer, Wieland , Ostrosky‐Zeichner, Luis , Redhead, Scott A. , Stevens, Bryan, Wang, Qiming , Zhang, Sean X.

Mayo Clinic

Journal of Clinical Microbiology | October 26, 2023 | Volume: 61 | Issue: 11 | Pages: No page available

10.1128/jcm.00873-23 | PMID 37882528 Get It

ABSTRACT The rapid pace of name changes of medically important fungi is creating challenges for clinical laboratories and clinicians involved in patient care. We describe two sources of name change which have different drivers, at the species versus the genus level. Some suggestions are made here to reduce the number of name changes. We urge taxonomists to provide diagnostic markers of taxonomic novelties. Given the instability of phylogenetic trees due to variable taxon sampling, we advocate to maintain genera at the largest possible size. Reporting of identified species in complexes or series should where possible comprise both the name of the overarching species and that of the molecular sibling, often cryptic species. Because the use of different names for the same species will be unavoidable for many years to come, an open access online database of the names of all medically important fungi, with proper nomenclatural designation and synonymy, is essential. We further recommend that while taxonomic discovery continues, the adaptation of new name changes by clinical laboratories and clinicians be reviewed routinely by a standing committee for validation and stability over time, with reference to an open access database, wherein reasons for changes are listed in a transparent way.
Muscle fiber phenotype: a culprit of abnormal metabolism and function in skeletal muscle of humans with obesity
Serrano, Nathan , Hyatt, Jon‐Philippe K. , Houmard, Joseph A. , Murgia, Marta , Katsanos, Christos S. , Katsanos, Christos S

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | October 25, 2023 | Volume: 325 | Issue: 6 | Pages: E723-E733

10.1152/ajpendo.00190.2023 | PMID 37877797 Get It

The proportion of the different types of fibers in a given skeletal muscle contributes to its overall metabolic and functional characteristics. Greater proportion of type I muscle fibers is associated with favorable oxidative metabolism and function of the muscle. Humans with obesity have a lower proportion of type I muscle fibers. We discuss how lower proportion of type I fibers in skeletal muscle of humans with obesity may explain metabolic and functional abnormalities reported in these individuals. These include lower muscle glucose disposal rate, mitochondrial content, protein synthesis, and quality/contractile function, as well as increased risk for heart disease, lower levels of physical activity, and propensity for weight gain/resistance to weight loss. We delineate future research directions and the need to examine hybrid muscle fiber populations, which are indicative of a transitory state of fiber phenotype within skeletal muscle. We also describe methodologies for precisely characterizing muscle fibers and gene expression at the single muscle fiber level to enhance our understanding of the regulation of muscle fiber phenotype in obesity. By contextualizing research in the field of muscle fiber type in obesity, we lay a foundation for future advancements and pave the way for translation of this knowledge to address impaired metabolism and function in obesity.
Late Development of Pneumatoceles in Necrotizing Pneumonia
Kocer, Sila Y. , NC, Hull, Potter, D. Dean , Madigan, Theresa , Boland-Froemming, Jennifer, Demirel, Nadir , Hull, Nathan C.

Mayo Clinic

No container title available | October 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.169808224.43398057/v1 Get It

Lymphatic Mapping with Contrast-enhanced Ultrasound for Lymphaticovenous Anastomosis Surgery: How We Do It
Jang, Samuel , Bustos, Samyd S. , Chen, Austin D. , Zheng, Eugene E., Hesley, Gina K. , Brinkman, Nathan , Carter, Jill S., Tran, Nho V. , Fahradyan, Vahe , Lee, Christine U. , Bustos, S S , Fahradyan, Vahe , Zheng, Eugene E.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | October 12, 2023 | Volume: 11 | Issue: 10 | Pages: e5328

10.1097/gox.0000000000005328 | PMID 37842077 Get It

Summary: Lymphaticovenous anastomosis (LVA) surgery is an effective surgery for the treatment of lymphedema in the extremities. Indocyanine green lymphography is the reference standard for visualizing lymphatics for LVA surgery, but it has several limitations; most notably, superficial dermal congestion can mask deeper lymphatic vessels. To overcome the limitations, we add contrast-enhanced ultrasound (CEUS) lymphography. We have previously reported that CEUS lymphography can identify lymphatic vessels for LVA surgery that indocyanine green lymphography does not. Here, we describe how we perform CEUS lymphography, including workflow, technique, and documentation. Before informed consent, the patient must be screened for possible adverse reactions to microbubbles. The procedure involves multiple intradermal injections of the microbubble agent at various sites along the extremity. After each injection, imaging for microbubble uptake by lymphatic vessels is performed using an ultrasound scanner with contrast-specific software. We use sulfur hexafluoride lipid-type A microspheres (Lumason/SonoVue; Bracco Suisse SA), but we are investigating the performance of other Food & Drug Administration–approved microbubble agents for CEUS lymphography. Having a systematic approach to marking the skin can mitigate the hindrance of marking over ultrasound coupling gel. Another benefit of CEUS lymphography is the rapid identification of neighboring veins compatible in size and location for anastomosis. We hold regular scheduled multidisciplinary meetings for coordination of care, discussion of outcomes, quality assurance, and ongoing innovation.
Pulmonary hemodynamics and transplant‐free survival in sarcoidosis‐associated pulmonary hypertension: Results from an international registry
Gayen, S. , Baughman, Robert P. , Nathan, Steven D. , Wells, Athol U. , Alhamad, Esam H. , Culver, Daniel A. , Barney, Joseph B. , Carmoma, Eva M., Cordova, Francis , Huitema, Marloes P. , Scholand, Mary Beth , Ganesh, Sivagini, Birring, Surinder S. , Wort, Stephen J. , Shlobin, Oksana A. , Gayen, Shameek K , Kouranos, Vasileios , Wijsenbeek, Marlies , Price, Laura , Gupta, Rohit

Mayo Clinic

Pulmonary Circulation | October 12, 2023 | Volume: 13 | Issue: 4 | Pages: No page available

10.1002/pul2.12297 | PMID 37840561 Get It

AbstractPulmonary hypertension (PH) is a risk factor for mortality in patients with sarcoidosis. Severe PH in chronic lung disease has previously been defined as mean pulmonary arterial pressure (mPAP) ≥ 35 mmHg or mPAP 25 ≥ mmHg with cardiac index (CI) ≤ 2 L/min/m2. However, there is no clear definition denoting severity of sarcoidosis‐associated PH (SAPH). We aimed to determine pulmonary hemodynamic cut‐off values where transplant‐free survival was worse among patients with SAPH. This was a retrospective cohort analysis of the Registry of SAPH database focusing on pulmonary hemodynamic predictors of transplant‐free survival among patients with precapillary SAPH. Cox regression was performed to determine which pulmonary hemodynamic values predicted death or lung transplantation. Kaplan−Meier survival analysis was performed on statistically significant predictors to determine pulmonary hemodynamic cut‐off values where transplant‐free survival was decreased. Decreased transplant‐free survival occurred among SAPH patients with mPAP ≥ 40 mmHg and SAPH patients with pulmonary vascular resistance (PVR) ≥ 5 Woods units (WU). Transplant‐free survival was not decreased in patients who fulfilled prior criteria of severe PH in chronic lung disease. We identified new cut‐offs with decreased transplant‐free survival in the SAPH population. Neither cut‐off of mPAP ≥ 40 mmHg nor PVR ≥ 5 WU has previously been shown to be associated with decreased transplant‐free survival in SAPH. These values could suggest a new definition of severe SAPH. Our PVR findings are in line with the most recent European Society of Cardiology/European Respiratory Society guideline definition of severe PH in chronic lung disease.
Biomarkers of cellular senescence and risk of death in humans
Weston, Susan A., Atkinson, Elizabeth J. , Gree, Michaela E. Mc, White, Thomas A. , Heeren, Amanda A., Rocca, Walter A. , Palmer, Allyson K. , Cummings, Steven R. , Fielding, Roger A. , St Sauver, Jennifer L , Mc Gree, Michaela E, Palmer, Allyson K , Bielinski, Suzette J. , LeBrasseur, Nathan K , Sauver, Jennifer L. St. , Mielke, Michelle M. , Olson, Janet E. , LeBrasseur, Nathan K.

Mayo Clinic

Aging Cell | October 8, 2023 | Volume: 22 | Issue: 12 | Pages: No page available

10.1111/acel.14006 | PMID 37803875 Get It

AbstractA robust and heterogenous secretory phenotype is a core feature of most senescent cells. In addition to mediators of age‐related pathology, components of the senescence associated secretory phenotype (SASP) have been studied as biomarkers of senescent cell burden and, in turn, biological age. Therefore, we hypothesized that circulating concentrations of candidate senescence biomarkers, including chemokines, cytokines, matrix remodeling proteins, and growth factors, could predict mortality in older adults. We assessed associations between plasma levels of 28 SASP proteins and risk of mortality over a median follow‐up of 6.3 years in 1923 patients 65 years of age or older with zero or one chronic condition at baseline. Overall, the five senescence biomarkers most strongly associated with an increased risk of death were GDF15, RAGE, VEGFA, PARC, and MMP2, after adjusting for age, sex, race, and the presence of one chronic condition. The combination of biomarkers and clinical and demographic covariates exhibited a significantly higher c‐statistic for risk of death (0.79, 95% confidence interval (CI): 0.76–0.82) than the covariates alone (0.70, CI: 0.67–0.74) (p < 0.001). Collectively, these findings lend further support to biomarkers of cellular senescence as informative predictors of clinically important health outcomes in older adults, including death.
Association Between Whole Blood–Derived Mitochondrial DNA Copy Number, Low‐Density Lipoprotein Cholesterol, and Cardiovascular Disease Risk
Liu, Xue , Sun, Xianbang, Jiang, Wenqing , Lai, M M , Wiggins, Kerri L. , Raffield, Laura M. , Bielak, Lawrence F. , Zhao, Wei , Pitsillides, Achilleas , Haessler, Jeffrey, Blackwell, Thomas W. , Yao, Jie , Qian, Yong , Thyagarajan, Bharat , Peyser, Patricia A. , Heckbert, Susan R. , Seshadri, Sudha , Boerwinkle, Eric , Grove, Megan L. , Larson, Nicholas B. , Smith, Jennifer A. , Fitzpatrick, Annette L., Fornage, Myriam , Ding, Jun , Carson, April P. , Reiner, Alex P. , Hou, Lifang , Wilson, James G. , Rotter, Jerome I. , Bis, Joshua C. , Arking, Dan E. , Zhao, Wei , Wiggins, Kerri L , Raffield, Laura M , Bielak, Lawrence F , Zhao, Wei , Pitsillides, Achilleas , Zheng, Yinan , Yao, Jie , Guo, Xiuqing , Thyagarajan, Bharat , Pankratz, Nathan , Rich, Stephen S , Taylor, Kent D , Peyser, Patricia A , Heckbert, Susan R , Boerwinkle, Eric , Larson, Nicholas B , Smith, Jennifer A , Vasan, Ramachandran S , Fornage, Myriam , Carson, April P , Dupuis, Josée , Reiner, Alexander P , Hou, Lifang , Psaty, Bruce M , Levy, Daniel , Rotter, Jerome I , Bis, Joshua C , Satizabal, Claudia L , Arking, Dan E , Liu, Chunyu , Seshadri, Sudha , Zhang, Yuankai , Zheng, Yinan , Guo, Xiuqing , Pankratz, Nathan , Rich, Stephen S. , Taylor, Kent D. , Vasan, Ramachandran S. , Abecasis, Gonçalo R. , Kooperberg, Charles , Psaty, Bruce M. , Levy, Daniel , Satizábal, Claudia L.

Mayo Clinic

Journal of the American Heart Association | October 7, 2023 | Volume: 12 | Issue: 20 | Pages: No page available

10.1161/jaha.122.029090 | PMID 37804200 Get It

Background The relationship between mitochondrial DNA copy number (mtDNA CN) and cardiovascular disease remains elusive. Methods and Results We performed cross‐sectional and prospective association analyses of blood‐derived mtDNA CN and cardiovascular disease outcomes in 27 316 participants in 8 cohorts of multiple racial and ethnic groups with whole‐genome sequencing. We also performed Mendelian randomization to explore causal relationships of mtDNA CN with coronary heart disease (CHD) and cardiometabolic risk factors (obesity, diabetes, hypertension, and hyperlipidemia). P <0.01 was used for significance. We validated most of the previously reported associations between mtDNA CN and cardiovascular disease outcomes. For example, 1‐SD unit lower level of mtDNA CN was associated with 1.08 (95% CI, 1.04–1.12; P <0.001) times the hazard for developing incident CHD, adjusting for covariates. Mendelian randomization analyses showed no causal effect from a lower level of mtDNA CN to a higher CHD risk (β=0.091; P =0.11) or in the reverse direction (β=−0.012; P =0.076). Additional bidirectional Mendelian randomization analyses revealed that low‐density lipoprotein cholesterol had a causal effect on mtDNA CN (β=−0.084; P <0.001), but the reverse direction was not significant ( P =0.059). No causal associations were observed between mtDNA CN and obesity, diabetes, and hypertension, in either direction. Multivariable Mendelian randomization analyses showed no causal effect of CHD on mtDNA CN, controlling for low‐density lipoprotein cholesterol level ( P =0.52), whereas there was a strong direct causal effect of higher low‐density lipoprotein cholesterol on lower mtDNA CN, adjusting for CHD status (β=−0.092; P <0.001). Conclusions Our findings indicate that high low‐density lipoprotein cholesterol may underlie the complex relationships between mtDNA CN and vascular atherosclerosis.
Nanoparticle Assembly: From Self‐Organization to Controlled Micropatterning for Enhanced Functionalities
Ravichandran, Dharneedar , Zhu, Yuxiang , Thippanna, Varunkumar , Ramanathan, Arunachalam , Patil, Dhanush , Fonseca, Nathan , Thummalapalli, Sri Vaishnavi , Sundaravadivelan, Barath , Sun, A. G. , Yang, Sui , Kannan, A.M. , Lancaster, Jessica N. , Joyee, Erina Baynojir , Song, Kenan , Ravichandran, Dharneedar , Zhu, Yuxiang , Thippanna, Varunkumar , Ramanathan, Arunachalam , Patil, Dhanush , Fonseca, Nathan , Thummalapalli, Sri Vaishnavi , Sundaravadivelan, Barath , Sun, Allen , Lancaster, Jessica, Song, Kenan , Lancaster, Jessica N , Jambhulkar, Sayli , Xu, Weiheng , Golan, Yuval , Chen, Lei

Mayo Clinic

Small | September 30, 2023 | Volume: 20 | Issue: 6 | Pages: No page available

10.1002/smll.202306394 | PMID 37775949 Get It

AbstractNanoparticles form long‐range micropatterns via self‐assembly or directed self‐assembly with superior mechanical, electrical, optical, magnetic, chemical, and other functional properties for broad applications, such as structural supports, thermal exchangers, optoelectronics, microelectronics, and robotics. The precisely defined particle assembly at the nanoscale with simultaneously scalable patterning at the microscale is indispensable for enabling functionality and improving the performance of devices. This article provides a comprehensive review of nanoparticle assembly formed primarily via the balance of forces at the nanoscale (e.g., van der Waals, colloidal, capillary, convection, and chemical forces) and nanoparticle‐template interactions (e.g., physical confinement, chemical functionalization, additive layer‐upon‐layer). The review commences with a general overview of nanoparticle self‐assembly, with the state‐of‐the‐art literature review and motivation. It subsequently reviews the recent progress in nanoparticle assembly without the presence of surface templates. Manufacturing techniques for surface template fabrication and their influence on nanoparticle assembly efficiency and effectiveness are then explored. The primary focus is the spatial organization and orientational preference of nanoparticles on non‐templated and pre‐templated surfaces in a controlled manner. Moreover, the article discusses broad applications of micropatterned surfaces, encompassing various fields. Finally, the review concludes with a summary of manufacturing methods, their limitations, and future trends in nanoparticle assembly.
Hourglass, a rapid analysis framework for heterogeneous bioimaging data, identifies sex disparity in IL‐6/STAT3‐associated immune phenotypes in pancreatic cancer
Aliar, Kazeera , Waterhouse, Henry R. , Vyas, Foram , Krebs, Niklas , Zhang, Bowen , Poulton, Emily , Chan, Nathan , González, Ricardo , Jang, Gun Ho , Bronsert, Peter , Gallinger, Steven , Grünwald, Barbara T , Khokha, Rama , Chan, Nathan , Gonzalez, Ricardo , Fischer, Sandra Elisabeth

Mayo Clinic

The Journal of Pathology | September 28, 2023 | Volume: 261 | Issue: 4 | Pages: 413-426

10.1002/path.6199 | PMID 37768107 Get It

AbstractIntegration and mining of bioimaging data remains a challenge and lags behind the rapidly expanding digital pathology field. We introduce Hourglass, an open‐access analytical framework that streamlines biology‐driven visualization, interrogation, and statistical assessment of multiparametric datasets. Cognizant of tissue and clinical heterogeneity, Hourglass systematically organizes observations across spatial and global levels and within patient subgroups. Applied to an extensive bioimaging dataset, Hourglass promptly consolidated a breadth of known interleukin‐6 (IL‐6) functions via its downstream effector STAT3 and uncovered a so‐far unknown sexual dimorphism in the IL‐6/STAT3‐linked intratumoral T‐cell response in human pancreatic cancer. As an R package and cross‐platform application, Hourglass facilitates knowledge extraction from multi‐layered bioimaging datasets for users with or without computational proficiency and provides unique and widely accessible analytical means to harness insights hidden within heterogeneous tissues at the sample and patient level. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.